Novel Avenanthramide Derivatives as Muco-Protective Agents in Cancer Therapy-Induced Oral Mucositis
Scientific-Disciplinary Group
06/MEDS-09 - Blood Diseases, Oncology And Rheumatology
Description
Oral mucositis (OM) is one of the most common inflammatory complications in cancer patients. The onset of OM often requires a reduction in dosage or suspension of antineoplastic therapy, highlighting the urgent need for effective preventive and therapeutic strategies. Avenanthramides have been shown to have protective effects on epithelial tissues, but their limited use is due to poor bioavailability. The project aims to elucidate the mucoprotective properties of synthetic avenanthramide derivatives (XX-AVE) previously selected as ideal candidates due to their high bioavailability. In the first phase, the mucoprotective effects of XX-AVE will be estimated using in vitro cell models composed of SG and MUR oral lines. Subsequently, the most effective compounds will be analyzed using advanced proteomic approaches in order to identify the molecular pathways involved in their mucoprotective activity.
Compensation
22,500 Euro
Job posting website
Number of positions
1
Maximum duration
12.0
Funding body
Università di Torino
How to apply
Selection process
Click to expand
View the original posting on the MUR website: Go to MUR website